WooGene B&G Co., Ltd (KOSDAQ:018620)
South Korea · Delayed Price · Currency is KRW 692.00
0.00 (0.00%)
At close: Mar 31, 2026
WooGene B&G Revenue
In the year 2025, WooGene B&G had annual revenue of 54.76B KRW, down -1.65%. WooGene B&G had revenue of 13.48B in the quarter ending December 31, 2025, a decrease of -0.07%.
Revenue
54.76B
Revenue Growth
-1.65%
P/S Ratio
0.37
Revenue / Employee
553.17M
Employees
92
Market Cap
19.99B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 54.76B | -915.98M | -1.65% |
| Dec 31, 2024 | 55.68B | -2.24B | -3.87% |
| Dec 31, 2023 | 57.92B | 14.22B | 32.53% |
| Dec 31, 2022 | 43.70B | 4.36B | 11.07% |
| Dec 31, 2021 | 39.35B | -176.99M | -0.45% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2012 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Hurum | 99.01B |
| ChoA Pharmaceutical Co., LTD. | 59.31B |
| CXI Healthcare Technology Group | 54.16B |
| Seoul Pharma | 52.15B |
| Kwangdong Healthbio | 38.10B |
| Union Korea Pharm | 33.83B |
| Daesung Microbiological Labs. | 25.99B |
| BIFIDO | 19.68B |